June 25, 2019
As part of our commitment to broad stakeholder education about the promise of biosimilars, the Biosimilars Council will launch the first in a series of “member spotlights” – in-depth content featuring experts from AAM member companies sharing their unique experience and perspective on timely issues impacting the emerging biosimilars marketplace.
We are excited to share with the broader stakeholder community the expertise and resources that each of these individuals brings to these important discussions. We’ll tackle important topics like regulatory policy, scientific development and patient access. Each spotlight features Q&A, blogs, social media content and videos on a timely topic of relevance to the emerging biosimilar marketplace, to help our stakeholders gain a deeper understanding of the promise of biosimilars for their communities. We hope you enjoy this deep dive into biosimilars and encourage you to share our resources with your networks interested in learning more about the industry.
Executive Director, Scientific Affairs, Sandoz, Inc.,
Hillel P. Cohen, Ph.D., Executive Director, Scientific Affairs, Sandoz, Inc., is a leading industry voice on biosimilars and biosimilar policy. With nearly two decades of experience working in biosimilars and “follow-on protein products,” Hillel has been instrumental in propelling the U.S. biosimilars industry forward. In particular, Hillel’s thought leadership on naming, interchangeability and broader biosimilars regulatory policy has helped position biosimilars as a solution for U.S. patients.